Aspire-Lakewood (ASBP) vs CytoMed Therapeutics (GDTC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Aspire-Lakewood (ASBP) has outperformed CytoMed Therapeutics (GDTC) over the past year, losing 38.4% versus a loss of 60.4%. Aspire-Lakewood is the larger company by market cap ($11.6 million vs $10.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASBP | GDTC |
|---|---|---|
| Share price | $8.30 | $0.89 |
| Market cap | $11.64M | $10.62M |
| 1-day change | 0.00% | -5.81% |
| YTD return | +57.20% | -33.33% |
| 1-year return | -38.43% | -60.44% |
| EPS (TTM) | $-30.89 | $-0.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.76 | $3.68 |
| 52-week low | $0.11 | $0.68 |
| Distance from 52-week high | -55.76% | -75.82% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +367.42% |
| Average volume | 37.15K | 79.04K |
| Shares outstanding | 1.40M | 11.93M |
| Employees | — | 42 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ASBP has outperformed GDTC by 22.0 percentage points over the past year.
About Aspire-Lakewood
ASBP stock →Aspire-Lakewood Holdings, Inc. develops sublingual drug delivery technology and manufactures automotive and industrial control systems.
Health Care · Biotechnology: Pharmaceutical Preparations
About CytoMed Therapeutics
GDTC stock →CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.
Health Care · Biotechnology: Pharmaceutical Preparations · 42 employees
ASBP vs GDTC FAQ
Which is bigger, Aspire-Lakewood or CytoMed Therapeutics?
Aspire-Lakewood (ASBP) is larger, with a market capitalization of $11.64M compared with $10.62M for CytoMed Therapeutics (GDTC).
Which stock has performed better over the past year, ASBP or GDTC?
ASBP returned -38.43% over the past 12 months, compared with -60.44% for GDTC (price return, excluding dividends). Past performance does not predict future results.
Are Aspire-Lakewood and CytoMed Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.